This guide is intended to provide a summary of three studies which share retrospective clinical data on the use of the OsteoCool™ RF Ablation system for the palliative treatment of bone metastases. These publications were not sponsored by Medtronic.
INTRODUCTION
Cancer invades bone in 60% to 80% of patients with metastatic disease 1 -most frequently among patients with primary malignancies of the breast, prostate, and lung. 2 Pain, usually refractory, is the most frequent complaint, occurring in 79% of these patients. 3 Bone metastases can significantly impact patients' quality of life with pain, 4 fractures, decreased mobility, depression, 5 and anxiety. 6 And with patients living longer with their cancer, more are suffering from metastatic disease pain. 1, 2 
EARLY AND LASTING PAIN RELIEF IS A PRIMARY GOAL IN MANAGING BONE METASTASES.
Radiation therapy (RT) is the gold standard palliative treatment for patients with bone metastases. While radiofrequency ablation (RFA) is not meant to oppose or replace standard treatments, it may complement RT.
A feasibility study by Di Staso, et al., 7* measured pain scores and time to response with RT vs. RT + RFA*. Patients who received the combined therapy had overall better pain scores and faster palliation. 7 With low-power, bipolar RFA, energy is delivered through internally cooled electrodes to a precise ablation zone. Where indicated, subsequent augmentation during the RFA procedure, using the same access tools, stabilizes the fracture.
Low-power bipolar radiofrequency ablation and vertebral augmentation for the palliative treatment of spinal malignancies Last clinical follow-up: 1.9 ± 1.4 months Mean pain score: 3.5 ± 2 at follow-up versus 7.8 ± 1.1 at baseline N=11 § Statistically significant pain reduction in 11/11 (100%) at follow-up (mean 1.9 ± 1.4 months) § Double electrode approach used in 10/11 (90.9%) of cases § Following RFA, all treated levels received vertebral augmentation § Metastatic epidural involvement was noted in 81.8% (9/11) cases § Technical success achieved in 100% of cases 
PROCEDURE
Using fluoroscopic-guided imaging, 10-gauge introducer needles were advanced into the T11, T12, and L1 vertebral levels using a bilateral transpedicular approach.
Simultaneous bipedicular 20 mm probes were advanced into the T11, T12, and L1 vertebral cavities. Radiofrequency energy was delivered for approximately 15 minutes, followed by vertebroplasty in all three levels to provide vertebral stability. (Figure 1) No complications occurred during the surgery and the patient was discharged the same day. Internally cooled probes create large volume lesions without excessive heating at the active tip, minimizing potential for char and risk of iatrogenic nerve damage.
At a target temperature of 70° C at the distal tip, the probes ablate for the pre-set time and yield predictable ablation zones.
Where indicated, use the same bone access for subsequent physician-directed procedure such as cementoplasty (i.e., kyphoplasty or vertebroplasty).
INDICATIONS AND RISKS
The OsteoCool™ RF Ablation System is intended for ablation of benign bone tumors such as osteoid osteoma and for the palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body. It is also intended for coagulation and ablation of tissue in bone during surgical procedures, including palliation of pain associated with metastatic lesions involving bone in patients who have failed or are not candidates for standard therapy. Risks of the system include damage to surrounding tissue through iatrogenic injury as a consequence of electrosurgery, pulmonary embolism, nerve injury including thermal injury, puncture of the spinal cord or nerve roots potentially resulting in radiculopathy, paresis, and paralysis. The OsteoCool™ bone access kits are indicated for percutaneous access to bone.
Kyphon™ BKP and vertebroplasty is a minimally invasive procedure for the treatment of pathological fractures of the vertebral body due to osteoporosis, cancer, or benign lesion. Risks of acrylic bone cements include cement leakage, which may cause tissue damage, nerve or circulatory problems, and other serious adverse events, such as: cardiac arrest, cerebrovascular accident, myocardial infarction, pulmonary embolism, or cardiac embolism.
Simultaneous ablation allows two probes to be positioned closely enough to produce large ablation zones.
